What are the primary FDA approval pathways for drugs, biologics, and medical devices?

The FDA uses different approval routes depending on the product. Drugs typically move through an IND followed by an NDA, while biologics progress through an IND and then a BLA due to their complexity. Medical devices are regulated based on risk and may require 510(k) clearance, De Novo classification, or Premarket Approval. Knowing the right pathway early helps streamline development.

What strategic elements play the biggest role in achieving FDA approval?

Success with the FDA depends on early regulatory planning, frequent communication with the agency, a clear Target Product Profile, strong manufacturing controls, and well-prepared clinical and nonclinical strategies. Companies that take a proactive approach generally face fewer regulatory challenges.

How is the regulatory evaluation of biologics different from that of traditional small-molecule drugs?

Biologics are derived from living systems and are more sensitive to manufacturing changes. Their regulatory pathway usually involves a BLA and requires extensive analytical, clinical, and quality data. In contrast, small-molecule drugs follow the NDA pathway and rely more on chemical characterization and controlled synthesis.

What challenges do companies commonly face when navigating FDA approval?

Common challenges include unclear regulatory pathways, inadequate manufacturing readiness, insufficient clinical planning, delayed FDA engagement, and lack of preparedness for inspections or global regulatory coordination. These issues often lead to delays or additional information requests.

In what ways does the roadmap to FDA approval differ between drug and device development?

While both involve preclinical work, human studies, submission, and post-market activities, their requirements differ greatly. Drug and biologic programs emphasize clinical trials and detailed CMC data. Devices may focus more on engineering testing, software validation, and human factors, and may rely on predicate devices for 510(k) submissions.

FDA Requirements for Good Tissue Practices (GTP) and GMP in HCT/P and Stem Cell Therapies

The development of human cells, tissues, and cellular and tissue-based products (HCT/Ps), including stem cell therapies, continues to expand opportunities in regenerative medicine. At the same time, manufacturers and healthcare organizations face increasingly important FDA expectations for product quality, donor safety, contamination control, traceability, and regulatory compliance. Understanding FDA HCT/P regulations, Good Tissue Practices (GTP), and GMP for HCT/Ps is therefore essential for organizations involved in cell and tissue recovery, processing, manufacturing, clinical development, and distribution.

Understanding FDA HCT/P Regulations

FDA regulates HCT/Ps primarily under 21 CFR Part 1271, with requirements addressing establishment registration and listing, donor eligibility, current good tissue practice, and other controls. FDA applies a risk-based framework that considers the potential for communicable disease transmission as well as risks associated with processing and intended use. HCT/Ps that meet all criteria under 21 CFR 1271.10 may be regulated solely under Section 361 of the Public Health Service Act, while products that do not meet those criteria may be subject to additional requirements, including premarket review. For stem cell and regenerative medicine products, regulatory classification is particularly important. FDA considers factors including whether an HCT/P is minimally manipulated and whether it is intended for homologous use when determining whether it falls within the Section 361 framework. Products outside that pathway may be regulated as biological products, drugs, or other applicable FDA-regulated products. Establishments that manufacture applicable HCT/Ps may also have registration and product-listing responsibilities under 21 CFR Part 1271. FDA states that establishments subject to registration generally must register and list their HCT/Ps within five days after beginning operations, with applicable updates required thereafter.

Good Tissue Practices and GMP Expectations

Good Tissue Practices (GTP) are central to controlling risks associated with HCT/P manufacturing. FDA’s Current Good Tissue Practice guidance addresses requirements covering facilities, environmental controls, equipment, supplies and reagents, recovery, processing and process controls, labeling, storage, distribution, donor eligibility, and records. These controls are intended primarily to prevent the introduction, transmission, or spread of communicable disease through HCT/Ps.For organizations developing more extensively processed cellular therapies, GMP for HCT/Ps becomes an important component of the broader manufacturing and quality framework applicable to the product. GMP principles require organizations to establish controlled and reproducible manufacturing processes supported by appropriate procedures, qualified personnel, suitable facilities and equipment, validated or appropriately qualified processes, quality oversight, investigations, CAPA, change control, and reliable documentation.

Donor eligibility is another critical area. FDA requires donor screening and testing for relevant communicable disease agents and diseases, subject to applicable regulatory exceptions. When an appropriate FDA-licensed, approved, or cleared donor screening test is available, FDA requires its use as specified in the regulations.Effective traceability is equally important. Organizations should be able to connect donor information, processing activities, materials, equipment, testing, labeling, storage, and distribution records throughout the product lifecycle. Weak traceability can make it difficult to investigate deviations, identify affected products, or respond efficiently to potential safety concerns.

Recent FDA Developments and Compliance Risks

FDA’s regulatory attention in this area continues to evolve. In January 2025, FDA issued draft guidance addressing donor eligibility for HCT/Ps, along with draft recommendations concerning HIV, HBV, and HCV transmission risks. In May 2025, FDA also issued draft recommendations addressing risks associated with sepsis and Mycobacterium tuberculosis. These documents demonstrate FDA’s continuing focus on donor screening and infectious-disease risk management, although the identified draft guidances are expressly described by FDA as non-binding and not for implementation. For companies, compliance risks can arise when written procedures do not reflect actual practices or when quality systems fail to adequately control deviations and changes. Inadequate donor records, insufficient training, contamination-control weaknesses, poor documentation, ineffective investigations, inadequate CAPA, inappropriate environmental controls, and gaps in product traceability can all create regulatory concerns. Importantly, GTP and GMP should not be treated as paperwork exercises. A strong quality system must demonstrate that procedures are scientifically appropriate, consistently followed, documented, reviewed, and continuously improved. Management oversight and periodic internal audits can help organizations identify weaknesses before they become significant inspection findings.

Practical Implications for Stem Cell and HCT/P Manufacturers

For pharmaceutical, biotechnology, clinical research, medical device, and regenerative medicine organizations, regulatory planning should begin early in product development. Companies should clearly establish the product’s regulatory classification, applicable manufacturing requirements, donor eligibility strategy, process controls, quality responsibilities, and documentation expectations. Manufacturers should also monitor FDA guidance developments and assess whether changes in scientific knowledge or regulatory expectations require updates to donor screening, testing, manufacturing procedures, quality systems, or risk assessments. FDA’s 2025 tissue guidance activity illustrates why maintaining regulatory intelligence is important for organizations operating in this rapidly developing field. Organizations seeking practical instruction on FDA HCT/P regulations, Good Tissue Practices (GTP), and GMP for HCT/Ps can explore FDA MAP’s Good Tissue Practices and GMP for HCT/P and Stem Cell Therapies webinar. The program provides industry-focused insights into regulatory expectations, quality systems, documentation, and compliance considerations for HCT/P and cellular therapy operations.

This blog highlights key FDA requirements for Good Tissue Practices (GTP) and Good Manufacturing Practices (GMP) in HCT/P and stem cell therapies, covering donor eligibility, contamination control, documentation, traceability, and quality systems. Gain practical insights into GTP and GMP compliance for HCT/Ps and stem cell therapies through our webinar.

Frequently Asked Questions

1. How does FDA determine whether an HCT/P qualifies for regulation solely under Section 361 of the PHS Act?

FDA evaluates whether the product meets all applicable criteria in 21 CFR 1271.10, including minimal manipulation, homologous use, appropriate combination with other substances, and absence of systemic effect or dependence on the metabolic activity of living cells, subject to the applicable regulatory framework.

2. How should manufacturers integrate GTP and GMP requirements into an HCT/P quality system?

Manufacturers should establish a risk-based quality system that integrates donor eligibility, aseptic processing, contamination control, process controls, equipment qualification, documentation, deviation management, CAPA, change control, and traceability according to the product’s regulatory classification and manufacturing activities.

3. What manufacturing controls are most critical for stem cell and HCT/P products?

Critical controls include control of raw materials and reagents, facility and environmental controls, prevention of cross-contamination and mix-ups, validated or appropriately qualified processes, in-process testing, product identification and traceability, and documented quality oversight.

4. How can companies maintain FDA inspection readiness for HCT/P and cellular therapy operations?

Inspection readiness requires more than maintaining written SOPs. Companies should routinely assess actual manufacturing practices against procedures, verify training effectiveness, maintain complete donor and manufacturing records, investigate deviations thoroughly, implement effective CAPA, and periodically conduct risk-based internal audits.

5. What regulatory challenges can arise when an HCT/P product undergoes changes in processing or intended use?

Changes in processing, manipulation, formulation, combination with other substances, or intended use can affect the product's regulatory classification and applicable FDA requirements. Sponsors should perform a documented regulatory assessment before implementing significant changes and determine whether additional FDA interaction or regulatory submissions may be necessary.